ExceleraRx, a national specialty pharmacy network, last week named James Fox as its president and CEO, effective Sept. 1.
Sandoz last week announced the U.S. market introduction of decitabine for injection, a generic version of Eisai’s Dacogen.
More than 55% of people suffer from swallowing difficulties when taking tablets or capsules, which is likely to inhibit compliance, according to an international survey conducted by Spiegel Institute Mannheim on behalf of Hermes Pharma.
UCB on Monday announced that the Food and Drug Administration has approved a supplemental new drug application for Vimpat (lacosamide) C-V as monotherapy in the treatment of partial-onset seizures in patients with epilepsy ages 17 years and older.
Pfizer last week announced that the Food and Drug Administration has granted fast track designation to the company’s investigational Clostridium difficile (C. difficile) vaccine candidate (PF-06425090).
Pfizer and Protalix BioTherapeutics last week announced that the Food and Drug Administration approved Elelyso (taliglucerase alfa) for injection for pediatric patients.
Rx Safes, manufacturer of fingerprint recognition home prescription lockboxes, on Thursday announced that it is waging a new war on drugs to reduce prescription drug abuse, backed by a national media campaign.
The steep decline in the use of hormone therapy has spawned a prevalent but preventable side effect: Millions of women suffering in silence with hot flashes, according to a study by a Yale School of Medicine researcher and colleagues.
Walgreens on Wednesday announced a tetanus, diphtheria, pertussis (Tdap) vaccination voucher program, in collaboration with the Alaska Department of Health and Social Services, to help protect against pertussis (whooping cough).
H. D. Smith on Monday announced the winners of its annual Trading Partners of the Year award, honoring select pharmaceutical and health products manufacturers who collaborate actively to grow the industry and advance patient care.